Product
Navepegritide + Lonapegsomatropin
1 clinical trial
1 indication
Indication
AchondroplasiaClinical trial
A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With AchondroplasiaStatus: Not yet recruiting, Estimated PCD: 2025-07-01